Shilpa Medicare Limited is the first company to receive approval for Manufacturing & Market of Pemetrexed Injection 10 ml, 50 ml, 85 ml, and 100 ml in India
The product basket increased to 1800 medicines and 285 Surgical Equipment
The net profit in the June quarter was also lower than Rs 146.3 crore reported in the March quarter.
India’s bioeconomy jumped from $8 billion in 2014 to $100 billion and the country now targets $150 billion by 2025
Advances clinical research capabilities with leading regulatory grade registries platform
PrecisionLife to analyse OXEGENE data to improve mechanistic understanding of endometriosis and identify novel drug targets to support the development of new personalised treatments
Adding 20,000 liters of installed biologics drug substance manufacturing capacity
The company is already marketing the 4 mg and 10 mg strengths
Subscribe To Our Newsletter & Stay Updated
